Nutriband completes market assessment for AVERSA Buprenorphine

Nutriband has completed the market assessment and commercialization strategy for AVERSA Buprenorphine, an abuse deterrent buprenorphine transdermal system. The company engaged leading healthcare consulting company Health Advances to assess the market opportunity and commercial strategy for Aversa Buprenorphine, which has the potential to be the world’s first buprenorphine transdermal system with abuse deterrent properties. Once approved by the United States FDA, Aversa Buprenorphine will be priced competitively with non-abuse deterrent options and may reach peak annual US sales of $70-130 million. The company is also considering developing the product for strategic international markets as protected by its global abuse deterrent patent portfolio.